MENU
NOV 15, 2018 2:00 AM PST

Towards commercial manufacture of pluripotent stem cell derived therapies

Speaker

Abstract

In contrast to autologous cell therapies, allogeneic therapies do not require collection of starting material from patients and could: be manufactured in larger batches, be made available “off-the-shelf”, and potentially utilise established biopharma manufacturing technologies. Despite this, allogeneic therapies constitute half of pre-clinical trials and a third of clinical trials in the UK. In an addition to the potential for an immune response, another major barrier to the adoption of allogeneic therapies is current manufacturing cost which increases when using pluripotent stem cells (PSC) as starting material. The manufacturing process is often open and manual, utilising 2D, adherent culture systems and xeno or serum containing materials. As such, these processes are regulatorily challenging and impractical to scale-up to meet market demands. This talk will cover our work to date and future plans in addressing these barriers and realising the potential of PSC-derived allogeneic therapies.

The Cell and Gene Therapy (CGT) Catapult have been working to address some of the challenges of manufacturing processes for PSC derived therapies, towards improving commercial viability. We used regulatorily amenable starting materials, developed invasive and non-invasive methods for process characterisation, developed exemplar processes for the expansion of pluripotent aggregates in stirred tank reactors, and developed concentration and wash processes for large-scale PSC processing. CGT Catapult’s next development focuses are the scale-up and intensification of PSC expansion in stirred tank reactors, translation of differentiation processes to automated and scalable culture systems, and cost of goods reduction.


Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
NOV 09, 2021 11:00 AM PST
C.E. CREDITS
NOV 09, 2021 11:00 AM PST
Date: November 09, 2021 Time: 11:00am (PDT), 02:00pm (EDT) Clinical translation of human pluripotent stem cells (hPSCs) requires advanced strategies that ensure safe and robust long-term gro...
JUL 13, 2021 11:00 AM PDT
C.E. CREDITS
JUL 13, 2021 11:00 AM PDT
Date: July 13, 2021 Time: 11:00am (PDT), 1:00pm (EDT) 1 R&D, Cell Culture & Fermentation Sciences, Bio Pharmaceutical Development, AstraZeneca, Gaithersburg, USA, 2 R&D, ADPE, Ce...
SEP 29, 2021 11:00 AM PDT
C.E. CREDITS
SEP 29, 2021 11:00 AM PDT
Date: Septembr 29, 2021 Time: 11:00am (PDT), 2:00pm (EDT) 3D cell models are becoming increasingly popular for studying complex biological effects, tissue functionality, and diseases. While...
NOV 17, 2021 8:00 AM PST
C.E. CREDITS
NOV 17, 2021 8:00 AM PST
Date: November 17, 2021 Time: 8:00am (PDT), 11:00am (EDT) From waste disposal to promising biomarkers and therapeutic agents, exosomes and other extracellular vesicles are valuable in resear...
NOV 15, 2018 2:00 AM PST

Towards commercial manufacture of pluripotent stem cell derived therapies



Show Resources
Loading Comments...
Show Resources